MAVEN Program for Enhancing Diversity in Scientific Leadership

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Northwell Health

Disqualifiers: Years from degree, Under-represented, Grant funding

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 2

160 Participants Needed

Trial Summary

What is the purpose of this trial?

MAVEN is an education training program designed to expand the national pool of qualified women and minority candidates for senior scientist positions across all NIGMS areas of science. Senior scientists (N=160, N=40 per cohort) belonging to an ethnicity, race or gender under-represented at the senior levels of faculty will be enrolled in a randomized 2-arm trial to determine the effects of the MAVEN intervention (comprised of virtual educational sessions and ongoing mentorship) on the following outcomes: 1) increased career satisfaction (primary outcome); 2) peak academic productivity; 3) expanded scientific networks; and 4) leadership ascension.

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications.

What safety data exists for the MAVEN Program for Enhancing Diversity in Scientific Leadership treatment?

The research highlights the importance of accurately identifying and reporting adverse events (unintended effects of medication) in clinical trials. A computerized system improved the detection of these events, reducing errors and allowing for early identification of potential risks, which helps ensure participant safety. ^{1 2 3 4 5}

How does the MAVEN treatment differ from other treatments for enhancing diversity in scientific leadership?

The MAVEN treatment is unique because it focuses on teaching leadership skills specifically to mid-career women scientists, particularly those from underrepresented groups, to help them advance into leadership positions in science and science policy. This approach addresses the critical career stage following promotion to associate or tenured professor, where traditional career development efforts often decline. ^{6 7 8 9 10}

Research Team

Karina Davidson, PhD, MASc

Principal Investigator

Northwell Health

Eligibility Criteria

The MAVEN trial is for scientists who are 10 to 15 years from their terminal degree, have at least one funded R01 level grant, and belong to an ethnicity, race or gender under-represented in senior faculty roles. It's not for those outside the 10-15 year range or who don't meet the diversity criteria.

Inclusion Criteria

I received my highest degree in my field 10-15 years ago.

I belong to an under-represented group in senior faculty levels.

Have one or more funded R01 level grant (or equivalent level grant)

Exclusion Criteria

I do not belong to an under-represented group in senior faculty levels.

Do not have one or more funded R01 level grant (or equivalent level grant)

I received my highest degree in my field either less than 10 years ago or more than 15 years ago.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Virtual Institutes

Participants in the MAVEN group receive two 7-day virtual institutes focused on career planning and leadership

2 weeks

2 virtual sessions

Mentorship and Networking

10 months of mentorship, networking, and conduct of institutional change projects

10 months

Follow-up

Participants are monitored for changes in career satisfaction, academic productivity, network size, and leadership ascension

5 years

Treatment Details

Interventions

• MAVEN

Trial Overview MAVEN is testing an educational program with virtual sessions and mentorship aimed at improving career satisfaction, productivity, networking, and leadership positions among minority senior scientists.

Participant Groups

Group I: MAVEN Experimental Treatment 1 Intervention

Group II: Control Active Control 1 Intervention

Participants enrolled in the control group will receive no mentoring activities but will complete all study measures and assessments.

Who Is Running the Clinical Trial?

Northwell Health

Lead Sponsor

Trials

481

Recruited

470,000+

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

National Institute of General Medical Sciences (NIGMS)

Collaborator

Trials

315

Recruited

251,000+

Findings from Research

The implementation of a computerized data management system for clinical trials significantly reduced transcription errors and overlooked adverse events, with errors dropping from 17% to 0% and overlooked events from 35% to 3%.

Using the computerized system also decreased the time needed to evaluate clinical information and report adverse events by 2-4 months, enhancing compliance with regulations and allowing for quicker identification of potential risks to patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of benefits derived from a computerized data management system for clinical trials data. Elting, LS., Bodey, GP.[2018]

A review of 99 completed allergic rhinitis trials found that while adverse events (AEs) were fully reported in ClinicalTrials.gov, only 46.7% of corresponding publications provided complete AE reporting, highlighting a significant gap in transparency.

Inconsistencies were prevalent in 95.6% of the publications, with discrepancies in the number and types of AEs reported, indicating a need for improved reporting standards to enhance patient safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Reporting of the safety from allergic rhinitis trials registered on ClinicalTrials.gov and in publications: An observational study. Paladin, I., Pranić, SM.[2022]

References

1. United States pubmed.ncbi.nlm.nih.gov

Evaluation of benefits derived from a computerized data management system for clinical trials data. [2018]

2. United States pubmed.ncbi.nlm.nih.gov

Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes. [2023]

3. England pubmed.ncbi.nlm.nih.gov

Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications. [2020]

4. England pubmed.ncbi.nlm.nih.gov

Reporting of the safety from allergic rhinitis trials registered on ClinicalTrials.gov and in publications: An observational study. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Standardized retrieval of side effects data for meta-analysis of safety outcomes. A feasibility study in acute sinusitis. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

Scientific Societies Advancing STEM Workforce Diversity: Lessons and Outcomes from the Minorities Affairs Committee of the American Society for Cell Biology. [2022]

7. England pubmed.ncbi.nlm.nih.gov

Introducing the MAVEN Leadership Training Initiative to diversify the scientific workforce. [2021]

8. United States pubmed.ncbi.nlm.nih.gov

Building Diverse Mentoring Networks that Transcend Boundaries in Cancer Research. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

The matilda effect in science: awards and prizes in the US, 1990s and 2000s. [2017]

10. England pubmed.ncbi.nlm.nih.gov

A participatory approach to evaluating a national training and institutional change initiative: the BUILD longitudinal evaluation. [2023]